Objective-To investigate eicosanoid concentrations in the saliva of patients with primary Sjogren's syndrome (SS). Methods-Whole mixed saliva of 36 subjects was assayed for eicosanoid concentrations using a radioimmunoassay. Patients with primary SS having positive lip biopsy served as the study group; their results were compared with data from patients with dry mouth and negative lip biopsy (dry mouth group), and with a group of normal healthy controls. Results-Concentrations of thromboxane B2 were significantly (p < 0.01) increased in 18 patients with primary SS compared with 10 patients with dry mouth and eight healthy normal controls (1-95 (SD 0-51) ng/ ml saliva compared with 0 52 (0-1) ng/ml and 0.3 (0.1) ng/ml, respectively). Similarly, prostaglandin E2 concentrations were also significantly increased (p < 0.01) in 11 patients with primary SS compared with five patients with dry mouth and eight normal controls (3.75 (0.82) ng/ml saliva compared with 0-32 (0.1) ng/ml and 0*41 (0-1) ngml, respectively). Conclusion-Salivary concentrations of eicosanoids are significantly increased in patients with primary SS, and this may prove helpful in the diagnosis of this disease.
Sjogren's syndrome (SS) is an autoimmune disease that causes destruction of salivary and tear glands and is associated with dryness of the eyes and mouth. The aetiology of this disease is not known, but its distinguishing histopathological characteristic is progressive lymphocytic infiltration of exocrine glands and other organs.' Evaluation of salivary gland involvement in SS is complicated and several diagnostic tools have been proposed, including the classical labial salivary gland biopsy,2 measurement of whole salivary flow, 3 (TxB2) in patients with Sjogren's syndrome (SS) and control groups. *p < 0 01 compared with other groups. ng/ml and 0-3 (0-1) ng/ml, respectively). Similarly, PGE2 concentrations were also significantly increased (p < 0 01) in 1 1 patients with primary SS compared with five patients with dry mouth and eight normal controls (3 75 (0.82) ng/ml saliva compared with 0-32 (0 1) ng/ml and 0-41 (0.1) ng/ml, respectively). No correlation was found between eicosanoid concentrations and various clinical or serological parameters.
Discussion
The salivary glands are a major target organ of inflammation in primary SS, resulting in poor secretory function and dry mouth (xerostomia). As subjective complaints of dry mouth are non-specific and occur in about 20% of the general population, involvement of the salivary glands as part of SS requires an objective test. Several methods have been proposed for assessment of salivary involvement in SS, including measurement of salivary flow rate, imaging procedures, and sialochemistry. None of these methods was found to be sufficiently sensitive or specific to be of use in diagnosis.'3 The presence of focal lymphocytic infiltrates composed mainly of CD4 positive T cells prompted us to seek inflammatory markers deriving from the salivary glands. These glands are suitable for the study of arachidonic acid metabolites because their product, saliva, is easily obtained for study and can be sampled by non-invasive methods.
We found a significant increase in PGE2 and TxB2 in patients with primary SS compared with normal controls and a dry mouth group. To the best of our knowledge, these findings are unique and have not been described before.
Increased concentrations of prostaglandins have been detected previously in patients with cystic fibrosis and in patients with a major depressive disorder.'4 '5 Both of these diseases are non-inflammatory in origin and therefore it is possible that an increased concentration of eicosanoids is no more than an epiphenomenon. One might speculate also that the increased concentrations of eicosanoids found in SS patients are a consequence of a small salivary volume; however, this is unlikely, as it has been shown that concentrations of arachidonic acid metabolites in whole mixed saliva are independent of salivary flow rate.'" The possibility that serum eicosanoids are filtered into the saliva has also been excluded. 7 The role of eicosanoids in immune inflammation is not clear. Prostaglandins may modify immune function by increasing the concentrations of cyclic AMP in lymphocytes; opposing effects of PGE2 on antibody production in vitro have also been described. The exact role of salivary eicosanoids is also not known, but it has been speculated that they participate in the defence mechanism of the oral cavity and in the absorption process of the gastrointestinal tract.9 1It has also been shown that salivary eicosanoids may play a part in the regulation of ion transport into the saliva.7 A defect in such sodium ion transport has been documented in several studies that revealed high sodium concentrations in the saliva of patients with primary SS."0 Our present results might explain these earlier reports.
In conclusion, we speculate that the increased salivary eicosanoid concentration found in patients with primary SS is a good indicator for the inflammatory process taking place in the salivary glands of these patients, and may support the diagnosis of this disease and help in the exclusion of patients who complain of dry mouth as a result of other causes.
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